Fosfomycin as Partner Drug for Systemic Infection Management. A Systematic Review of Its Synergistic Properties from In Vitro and In Vivo Studies
- PMID:32785114
- PMCID: PMC7460049
- DOI: 10.3390/antibiotics9080500
Fosfomycin as Partner Drug for Systemic Infection Management. A Systematic Review of Its Synergistic Properties from In Vitro and In Vivo Studies
Abstract
Fosfomycin is being increasingly prescribed for multidrug-resistant bacterial infections. In patients with systemic involvement, intravenous fosfomycin is usually administered as a partner drug, as part of an antibiotic regimen. Hence, the knowledge of fosfomycin pharmacodynamic interactions (synergistic, additive, indifferent and antagonistic effect) is fundamental for a proper clinical management of severe bacterial infections. We performed a systematic review to point out fosfomycin's synergistic properties, when administered with other antibiotics, in order to help clinicians to maximize drug efficacy optimizing its use in clinical practice. Interactions were more frequently additive or indifferent (65.4%). Synergism accounted for 33.7% of total interactions, while antagonism occurred sporadically (0.9%). Clinically significant synergistic interactions were mostly distributed in combination with penicillins (51%), carbapenems (43%), chloramphenicol (39%) and cephalosporins (33%) in Enterobactaerales; with linezolid (74%), tetracyclines (72%) and daptomycin (56%) inStaphylococcus aureus; with chloramphenicol (53%), aminoglycosides (43%) and cephalosporins (36%) againstPseudomonas aeruginosa; with daptomycin (97%) inEnterococcus spp. and with sulbactam (75%) and penicillins (60%) and inAcinetobacter spp. fosfomycin-based antibiotic associations benefit from increase in the bactericidal effect and prevention of antimicrobial resistances. Taken together, the presence of synergistic interactions and the nearly total absence of antagonisms, make fosfomycin a good partner drug in clinical practice.
Keywords: fosfomycin; infection; multidrug resistant; pharmacodynamic; synergic; synergism; synergistic.
Conflict of interest statement
The authors declare no conflict of interest.
Similar articles
- Daptomycin synergistic properties from in vitro and in vivo studies: a systematic review.Antonello RM, Canetti D, Riccardi N.Antonello RM, et al.J Antimicrob Chemother. 2022 Dec 23;78(1):52-77. doi: 10.1093/jac/dkac346.J Antimicrob Chemother. 2022.PMID:36227704
- New perspectives for reassessing fosfomycin: applicability in current clinical practice.Candel FJ, Matesanz David M, Barberán J.Candel FJ, et al.Rev Esp Quimioter. 2019 May;32 Suppl 1(Suppl 1):1-7.Rev Esp Quimioter. 2019.PMID:31131586Free PMC article.Review.
- Synergism of fosfomycin-ampicillin and fosfomycin-chloramphenicol against Salmonella and Shigella.Perea EJ, Torres MA, Borobio MV.Perea EJ, et al.Antimicrob Agents Chemother. 1978 May;13(5):705-9. doi: 10.1128/AAC.13.5.705.Antimicrob Agents Chemother. 1978.PMID:666297Free PMC article.
- A study on combination of daptomycin with selected antimicrobial agents: in vitro synergistic effect of MIC value of 1 mg/L against MRSA strains.Lee YC, Chen PY, Wang JT, Chang SC.Lee YC, et al.BMC Pharmacol Toxicol. 2019 May 6;20(1):25. doi: 10.1186/s40360-019-0305-y.BMC Pharmacol Toxicol. 2019.PMID:31060599Free PMC article.
- Intravenous Fosfomycin: An Assessment of Its Potential for Use in the Treatment of Systemic Infections in Canada.Zhanel GG, Zhanel MA, Karlowsky JA.Zhanel GG, et al.Can J Infect Dis Med Microbiol. 2018 Jun 25;2018:8912039. doi: 10.1155/2018/8912039. eCollection 2018.Can J Infect Dis Med Microbiol. 2018.PMID:30046362Free PMC article.Review.
Cited by
- Efficacy and Safety of Oral Fosfomycin-Trometamol in Male Urinary Tract Infections with Multidrug-Resistant Enterobacterales.Bouiller K, Zayet S, Lalloz PE, Potron A, Gendrin V, Chirouze C, Klopfenstein T.Bouiller K, et al.Antibiotics (Basel). 2022 Feb 3;11(2):198. doi: 10.3390/antibiotics11020198.Antibiotics (Basel). 2022.PMID:35203801Free PMC article.
- Multicenter Evaluation of the Novel ETEST Fosfomycin for Antimicrobial Susceptibility Testing of Enterobacterales, Enterococcus faecalis, and Staphylococcus Species.Goer A, Blanchard LS, Van Belkum A, Loftus KJ, Armstrong TP, Gatermann SG, Shortridge D, Olson BJ, Meece JK, Fritsche TR, Pompilio M, Halimi D, Franceschi C.Goer A, et al.J Clin Microbiol. 2022 Jul 20;60(7):e0002122. doi: 10.1128/jcm.00021-22. Epub 2022 Jun 23.J Clin Microbiol. 2022.PMID:35736011Free PMC article.
- Anti-infective management of infected skin ulcers.Di Bella S, Luzzati R, Mearelli F, Papa G, Spazzapan L, Nunnari A, D'Aleo F, Papola C, Principe L.Di Bella S, et al.Infez Med. 2024 Jun 1;32(2):138-147. doi: 10.53854/liim-3202-3. eCollection 2024.Infez Med. 2024.PMID:38827836Free PMC article.Review.
- Update on Coagulase-Negative Staphylococci-What the Clinician Should Know.Michels R, Last K, Becker SL, Papan C.Michels R, et al.Microorganisms. 2021 Apr 14;9(4):830. doi: 10.3390/microorganisms9040830.Microorganisms. 2021.PMID:33919781Free PMC article.Review.
- Prescription Pattern of Intravenous Fosfomycin in a Provincial Hospital in Thailand.Thampithak A, Chaisiri K, Siangsuebchart O, Phengjaturat K, Aonjumras W, Hemapanpairoa J.Thampithak A, et al.Infect Chemother. 2022 Dec;54(4):699-710. doi: 10.3947/ic.2022.0098. Epub 2022 Nov 11.Infect Chemother. 2022.PMID:36450288Free PMC article.
References
- Kaye K.S., Rice L.B., Dane A.L., Stus V., Sagan O., Fedosiuk E., Das A.F., Skarinsky D., Eckburg P.B., Ellis-Grosse E.J. Fosfomycin for Injection (ZTI-01) Versus Piperacillin-tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial. Clin. Infect. Dis. 2019;69:2045–2056. doi: 10.1093/cid/ciz181. - DOI - PMC - PubMed
- Falagas M.E., Kastoris A.C., Kapaskelis A.M., Karageorgopoulos D.E. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: A systematic review. Lancet. Infect. Dis. 2010;10:43–50. doi: 10.1016/S1473-3099(09)70325-1. - DOI - PubMed
- Zhanel G.G., Zhanel M.A., Karlowsky J.A. Oral Fosfomycin for the Treatment of Acute and Chronic Bacterial Prostatitis Caused by Multidrug-Resistant Escherichia coli. Can. J. Infect. Dis. Med. Microbiol. = J. Can. des Mal. Infect. la Microbiol. Medicale. 2018;2018:1404813. doi: 10.1155/2018/1404813. - DOI - PMC - PubMed
Publication types
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous